Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 375 of 672 entries
View as:

Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide

Phase: N/A Priority: Normal
NCT ID: NCT03580668 Org: User:
Start: 11/13/18 End: 06/03/24 Due: 06/03/25

Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02457559 Org: User:
Start: 09/10/15 End: 12/30/20 Due: 12/30/21

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Phase: N/A Priority: Normal
NCT ID: NCT03074331 Org: User:
Start: 03/23/17 End: 02/07/18 Due: 02/07/19

A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01101594 Org: User:
Start: 07/31/10 End: 07/31/13 Due: 07/31/14

Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT02128542 Org: User:
Start: 06/30/14 End: 06/30/15 Due: 06/30/16

Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea

Phase: N/A Priority: Normal
NCT ID: NCT02951364 Org: User:
Start: 12/05/16 End: 06/11/21 Due: 06/11/22

Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

Phase: N/A Priority: Normal
NCT ID: NCT02579382 Org: User:
Start: 11/10/15 End: 05/03/19 Due: 05/03/20

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT01369498 Org: User:
Start: 06/30/11 End: 09/24/14 Due: 09/24/15

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04892446 Org: User:
Start: 11/09/21 End: 04/25/24 Due: 04/25/25

Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04502706 Org: User:
Start: 11/17/20 End: 03/31/22 Due: 03/31/23

Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)

Phase: N/A Priority: Normal
NCT ID: NCT02574455 Org: User:
Start: 11/07/17 End: 12/08/20 Due: 12/08/21

Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Phase: N/A Priority: Normal
NCT ID: NCT02568683 Org: User:
Start: 02/11/16 End: 06/22/17 Due: 06/22/18

GMB: Study of Truvada (TDF+FTC) or Emtricitabine (FTC) Alone Versus HAART Interruption in HIV-Infected Patients With Resistance

Phase: N/A Priority: Normal
NCT ID: NCT00362687 Org: User:
Start: 11/30/06 End: 10/31/08 Due: 10/31/09

A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS

Phase: N/A Priority: Normal
NCT ID: NCT00002116 Org: User:
Start: - End: - Due: -

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT06051617 Org: User:
Start: 09/07/23 End: 08/31/30 Due: 08/31/31

Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00054834 Org: User:
Start: 03/31/03 End: - Due: -

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00040599 Org: User:
Start: 01/31/00 End: 01/31/04 Due: 01/31/05

Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)

Phase: N/A Priority: Normal
NCT ID: NCT00740610 Org: User:
Start: 08/31/08 End: 09/30/09 Due: 09/30/10

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection

Phase: N/A Priority: Normal
NCT ID: NCT01740791 Org: User:
Start: 11/06/12 End: 01/24/14 Due: 01/24/15

Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women

Phase: N/A Priority: Normal
NCT ID: NCT05281510 Org: User:
Start: 06/09/22 End: 01/16/25 Due: 01/16/26

Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Phase: N/A Priority: Normal
NCT ID: NCT01095796 Org: User:
Start: 03/31/10 End: 09/30/14 Due: 09/30/15

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

Phase: N/A Priority: Normal
NCT ID: NCT00224445 Org: User:
Start: 09/30/05 End: 01/31/07 Due: 01/31/08

Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT01779518 Org: User:
Start: - End: - Due: -

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT01363011 Org: User:
Start: 05/31/11 End: 02/28/15 Due: 02/28/16

Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3

Phase: N/A Priority: Normal
NCT ID: NCT01808248 Org: User:
Start: 02/28/13 End: 12/31/13 Due: 12/31/14